25,276 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Acquired by Diadema Partners LP

Diadema Partners LP acquired a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 25,276 shares of the biotechnology company's stock, valued at approximately $3,480,000. Ascendis Pharma A/S comprises approximately 1.5% of Diadema Partners LP's holdings, making the stock its 13th biggest holding.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC boosted its holdings in shares of Ascendis Pharma A/S by 2.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company's stock valued at $702,538,000 after acquiring an additional 114,167 shares during the last quarter. Stifel Financial Corp grew its position in Ascendis Pharma A/S by 36.1% during the 4th quarter. Stifel Financial Corp now owns 17,097 shares of the biotechnology company's stock worth $2,354,000 after purchasing an additional 4,534 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of Ascendis Pharma A/S by 195.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock valued at $138,000 after buying an additional 664 shares during the last quarter. Capital International Inc. CA acquired a new stake in Ascendis Pharma A/S during the fourth quarter worth about $1,153,000. Finally, Capital International Ltd. CA purchased a new position in Ascendis Pharma A/S during the fourth quarter valued at approximately $2,637,000.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on ASND shares. Morgan Stanley set a $180.00 price objective on shares of Ascendis Pharma A/S in a research note on Tuesday, February 18th. JPMorgan Chase & Co. lifted their price objective on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a report on Tuesday, March 18th. UBS Group initiated coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a "buy" rating and a $196.00 target price on the stock. The Goldman Sachs Group increased their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Finally, Royal Bank of Canada initiated coverage on Ascendis Pharma A/S in a research report on Wednesday, April 16th. They issued an "outperform" rating and a $205.00 price objective for the company. Two analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat, Ascendis Pharma A/S presently has an average rating of "Moderate Buy" and an average price target of $204.67.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND traded up $3.70 during trading on Friday, hitting $164.15. 560,181 shares of the company were exchanged, compared to its average volume of 489,499. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $169.37. The company has a fifty day moving average price of $153.78 and a 200-day moving average price of $138.97. The firm has a market capitalization of $10.01 billion, a PE ratio of -23.12 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.64. Research analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.